Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teele Kuusk

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
European Urology Oncology|February 26, 2026
Prediction Models for Shared Decision-making by Patients with Localised Renal Masses: A Systematic Review and a Survey of Patient and Clinician PrioritiesJames P Blackmur, Sabrina H Rossi, Teele Kuusk, et al.
Urology|August 7, 2017
Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell CarcinomaRoderick E de Bruijn, Teele Kuusk, Allard P Noe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2017
The Impact of Adding Sentinel Node Biopsy to Extended Pelvic Lymph Node Dissection on Biochemical Recurrence in Prostate Cancer Patients Treated with Robot-Assisted Radical ProstatectomyNikolaos Grivas, Esther M K Wit, Teele Kuusk, et al.
European Urology Oncology|December 22, 2021
Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor-based Dual Combination TherapyNiels M Graafland, Bernadett Szabados, Chandran Tanabalan, et al.
World Journal of Urology|February 26, 2021
Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomyTeele Kuusk, Tobias Klatte, Patricia Zondervan, et al.
European Urology Open Science|January 5, 2023
Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence GroupsLorenzo Marconi, Teele Kuusk, Umberto Capitanio, et al.
European Urology Oncology|January 21, 2020
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial DataRoderick de Bruijn, Akhila Wimalasingham, Bernadett Szabados, et al.
BJU International|July 12, 2025
Sentinel lymph node staging in urological cancer surgery: advances in imaging, intra-operative detection and translational researchErik J van Gennep, Gijs H KleinJan, Teele Kuusk, et al.
BJU International|April 13, 2026
Oligoprogressive renal cell carcinoma: What is the role of surgery?Chiara Re, William H J Ince, Leo Bickley, et al.
Future Oncology (London, England)|April 27, 2019
A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)Axel Bex, Johan V van Thienen, Mariette Schrier, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
European Urology Oncology|February 26, 2026
Prediction Models for Shared Decision-making by Patients with Localised Renal Masses: A Systematic Review and a Survey of Patient and Clinician PrioritiesJames P Blackmur, Sabrina H Rossi, Teele Kuusk, et al.
Urology|August 7, 2017
Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell CarcinomaRoderick E de Bruijn, Teele Kuusk, Allard P Noe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2017
The Impact of Adding Sentinel Node Biopsy to Extended Pelvic Lymph Node Dissection on Biochemical Recurrence in Prostate Cancer Patients Treated with Robot-Assisted Radical ProstatectomyNikolaos Grivas, Esther M K Wit, Teele Kuusk, et al.
European Urology Oncology|December 22, 2021
Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor-based Dual Combination TherapyNiels M Graafland, Bernadett Szabados, Chandran Tanabalan, et al.
World Journal of Urology|February 26, 2021
Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomyTeele Kuusk, Tobias Klatte, Patricia Zondervan, et al.
European Urology Open Science|January 5, 2023
Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence GroupsLorenzo Marconi, Teele Kuusk, Umberto Capitanio, et al.
European Urology Oncology|January 21, 2020
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial DataRoderick de Bruijn, Akhila Wimalasingham, Bernadett Szabados, et al.
BJU International|July 12, 2025
Sentinel lymph node staging in urological cancer surgery: advances in imaging, intra-operative detection and translational researchErik J van Gennep, Gijs H KleinJan, Teele Kuusk, et al.
BJU International|April 13, 2026
Oligoprogressive renal cell carcinoma: What is the role of surgery?Chiara Re, William H J Ince, Leo Bickley, et al.
Future Oncology (London, England)|April 27, 2019
A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)Axel Bex, Johan V van Thienen, Mariette Schrier, et al.
Pageof 6